摘要
目的探究替诺福韦酯与恩替卡韦治疗HBe Ag阳性慢性乙型肝炎(CHB)的效果。方法从本院2012年3月至2013年6月收治的HBe Ag阳性CHB患者80例,按照随机数表法随机抽取组成替诺福韦酯组和恩替卡韦组,每组40例。替诺福韦酯组给予300 mg·d-1替诺福韦酯治疗,恩替卡韦组采用0.5 mg·d-1恩替卡韦治疗。对2组患者治疗前的年龄、性别、HBV DNA定量和ALT水平进行检测比较;对2组患者治疗24周和48周后的ALT复转、HBe Ag阴转和HBV DNA阴转水平进行检测比较;对2组患者治疗48周后的HBV DNA高度应答率进行统计比较。结果治疗24周和48周后,替诺福韦酯组HBe Ag阴转水平均高于恩替卡韦组(P<0.05),HBV DNA阴转和ALT复常水平相似,差异无统计学意义(P>0.05);2组患者的HBV DNA高度应答率差异无统计学意义(P>0.05)。结论替诺福韦酯与恩替卡韦在治疗HBe Ag阳性CHB患者时,替诺福韦酯在患者HBe Ag阴转方面作用显著,安全性较高。
Objective To investigate the effect of tenofovir disoproxil fumarate and entecavir for HBe Ag-positive chronic hepatitis B（CHB）. Methods Totally 80 cases patients were selected from HBe Ag-positive CHB patients in our hospital from March 2012 to June 2013, which were divided into a tenofovir disoproxil fumarate group and an entecavir group, according to the random number table method, each group of 40 cases. Tenofovir disoproxil fumarate group was given daily times of 300 mg·d^- 1 tenofovir disoproxil fumarate, while entecavir group was given 0.5 mg·d^- 1 entecavir. Age, sex, HBV DNA and ALT levels of 2 groups were detected quantitatively; 24 weeks and 48 weeks after the transfer of ALT, HBe Ag seroconversion and HBV DNA levels were detected; the response rate 48 weeks after the treatment to the height of 2 groups with HBV DNA were detected. Results The HBe Ag seroconversion of tenofovir disoproxil fumarate group was higher than that of entecavir group（P〈 0.05）, but the HBV DNA and ALT normalization level had no significant difference（P 〉0.05）; HBV DNA response in the 2 groups had no significant difference（P 〉0.05）. Conclusion In the treatment of HBe Ag-positive CHB patients, tenofovir disoproxil fumarate has obvious effect on HBe Ag postive patients.
出处
《中南药学》
CAS
2015年第2期206-208,共3页
Central South Pharmacy
